英菲格拉替尼多久耐药

Infigratinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma who develop drug resistance within a few months or a year after taking infigratinib. In fact, many patients with cholangiocarcinoma will develop drug-resistant mutations after several years, so the time to drug resistance varies from person to person. Different patients have different conditions, different constitutions, and different drug resistance times.

The U.S. FDA announced the approval of Infigratinib (Truseltiq) on May 29, 2021, for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion and rearrangement mutations. The results of the trial showed that the overall response rate of patients treated with infigratinib was 23.1%, and the median progression-free survival was 7.3 months. Among the patients who responded, 32.0% had a response lasting more than 6 months, and the median response duration was 5.0 months.

The results of subgroup analysis showed that the overall response rate of patients who had received second-line treatment was 34%, and the overall response rate of patients who had received third-line treatment or above was 13.8%; the largest number of patients had received 8 front-line treatments.

The above-mentioned trials mentioned that the median progression-free survival was 7.3 months, which means that patients treated with infigratinib are effective for at least 7 months. If the disease does not progress, there is no resistance. It is recommended that patients pay attention to their body's reaction during treatment. If the condition worsens and they feel that the medicine has no effect after taking it, it is usually considered to be drug resistance. After drug resistance, it is recommended to go to the hospital for an examination and choose appropriate drug treatment according to the doctor's plan.

Infigratinib is a small molecule ATP-competitive tyrosine kinase inhibitor of FGFR that blocks downstream signaling cascades by selectively binding and inhibiting FGFR activity and inducing tumor cell death by reducing cancer cell proliferation. Patients should inform their doctors about the medications they take, including prescription drugs, over-the-counter drugs, and herbal products. Advise patients to avoid the use of grapefruit products during treatment with infigratinib.

Recommended related articles: